### Alert
Safety data for salbutamol in newborn infants are limited. It should be used with caution. Evidence for salbutamol in the treatment of respiratory disease and bronchospasm in neonates is poor.

### Indication
- Hyperkalaemia
- Bronchospasm (evidence for efficacy is lacking)

### Action
Stimulates liver and muscle cyclic AMP production causing potassium flow into cells.

### Drug Type
Sympathomimetic. \(\beta_2\)-agonist.

### Trade Name
**IV:** Ventolin Injection
**Inhalation:** APO-Salbutamol 2.5, Asmol uni-dose 2.5, Butamol 2.5, Chemmart Salbutamol 2.5, Pharmacer Salbutamol 2.5, Salbutamol Actavis 2.5, Salbutamol 2.5, Salbutamol Sandoz 2.5, Salbutamol Sterinebs 2.5, Salbutamol-GA 2.5, Salbutamol-GA 2.5, Ventolin Nebules 2.5

### Presentation
**IV:** 500 micrograms/mL ampoule
**Inhalation:** 1 mg/mL (2.5 mg in 2.5 mL) and 2 mg/mL (5 mg in 2.5 mL) inhalation solution ampoules.

### Dosage/Interval
**Intravenous:**
4–5 microgram/kg over 20 minutes.
Monitor serum potassium and heart rate (tachycardia) closely. If potassium critical or continues to rise, consider repeating dose or use of other strategy (insulin/glucose; addition of rectal cation-resin).

**Inhalation:**
400 microgram via nebulisation. Repeat two-hourly as required and titrated to response [serum potassium or respiratory status] and heart rate [tachycardia].

### Maximum daily dose
**Route**
IV, inhalation

### Preparation/Dilution
**IV:**
Draw up 0.4 mL (200 microgram) of salbutamol 500 microgram/mL ampoule and add 19.6 mL of WFI to make a final volume of 20 mL with a concentration of 10 microgram/mL. Further dilute: by drawing up 1 mL/kg of this solution (10 microgram/kg of salbutamol) and make up to 10 mL with WFI to make a solution with final concentration of 1 microgram/kg/mL.

**Inhalation:**
Draw up 0.4 mL (400 micrograms) of salbutamol 1 mg/mL inhalation ampoule and add 1.6 mL sodium chloride 0.9% to make a final volume of 2 mL. Draw up 0.2 mL (400 micrograms) of salbutamol 2 mg/mL inhalation ampoule and add 1.8 mL sodium chloride 0.9% to make a final volume of 2 mL.

### Administration
**Intravenous:**
Administer over 15–20 minutes via syringe driver.

**Inhalation:**
Administer via nebuliser.

### Monitoring
Monitor cardiac rate and rhythm, serum potassium, blood glucose

### Contraindications
Infants with tachycardia

### Drug Interactions
Non-selective beta-blockers may increase serum potassium.
Diuretics [hydrochlorothiazide, furosemide] increase risk of hypokalaemia and ECG changes.
Salbutamol decreases digoxin concentrations.

### Adverse Reactions
Tachycardia, tremor, hypokalaemia. There is some concern that a transient increase in serum potassium may occur in the first few minutes of treatment.\(^8\)

### Compatibility
IV fluids: Water for injection, glucose 5%, sodium chloride 0.9%, glucose 4% in sodium chloride 0.18%, lactated Ringer’s injection
**Incompatibility**

<table>
<thead>
<tr>
<th>IV fluids: No information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV Y-site: Pantoprazole.</td>
</tr>
<tr>
<td>Inhalation: No information</td>
</tr>
</tbody>
</table>

**Stability**

<table>
<thead>
<tr>
<th>IV: Ampoules should be used immediately after opening. Any unused solution should be discarded. Diluted solution stable for 24 hours below 25°C.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation: Ampoules should be used immediately after opening. Any unused solution should be discarded.</td>
</tr>
</tbody>
</table>

**Storage**

<table>
<thead>
<tr>
<th>IV ampoule: Store at room temperature below 30°C. Protect from light.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation ampoule: Store at room temperature below 25°C. Protect from light.</td>
</tr>
</tbody>
</table>

**Special Comments**

Cross-check the correct strength of salbutamol intravenous and inhalation ampoules are used.

**Evidence summary**

**Efficacy and safety**

**Treatment of hyperkalaemia:** A systematic review identified one study (Singh et al., 2002) of 19 infants which compared inhaled salbutamol [albuterol] versus placebo for non-oliguric hyperkalaemia (serum K⁺ 5–7.5 mmol/L) in premature newborns.² Inhaled salbutamol 400 microgram, repeated 2-hourly as required, reduced serum K⁺ from baseline at 4 hours (mean difference 0.69 mmol/L) and 8 hours (mean difference 0.59 mmol/L).³ All-cause mortality was not reduced and cardiac arrhythmia did not occur in either study group. There was no significant difference in severe IVH, tremor, hyperglycaemia or pulmonary haemorrhage.¹

A number of case reports and case series have been published documenting the efficacy of salbutamol by infusion for treatment of hyperkalaemia in the newborn. Greenhough et al reported the use of IV salbutamol 4 microgram/kg over 20 minutes in 10 consecutive neonates with hyperkalaemia.² The potassium fell in 7 of the 10 infants (range 0.7–1.8 mmol/L) but continued to rise in 3 infants, all of whom had a persistent metabolic acidosis.²

Murdoch et al reported on the use of IV salbutamol 4 microgram/kg over 20 minutes in 13 children (ages 0.01–16.7 years) with hyperkalaemia.³ The mean reduction in plasma potassium concentration was 1.48 mmol/L at 40 minutes and 1.64 mmol/L at 120 minutes.³

Kemper et al reported on the use of IV salbutamol at 5 microgram/kg over 20 minutes in 15 children (ages 0.1–16 years) with hyperkalaemia.⁴ The mean reduction in plasma potassium concentration was 0.87 mmol/L at 30 minutes and 1.69 mmol/L at 120 minutes. Transient tachycardia was detected in three patients.⁴

Recommendation: Salbutamol (either inhaled or intravenously administered) may be used in the treatment of hyperkalaemia in the neonate. Salbutamol may be useful in settings where hypoglycaemia limits the use of insulin. Salbutamol may have additive effects when used with insulin and glucose. Salbutamol appears to be generally safe with limited risk of tachycardia. (LOE II – III, GOR B).

**Treatment of respiratory disease:** Systematic review of 3 trials including 140 infants comparing salbutamol versus placebo in near term or term infants less than three days of age with transient tachypnoea of the newborn found a reduction in the duration of oxygen therapy (MD -43.10 hours, 95% CI -81.60 to -4.60), but no difference in the need for CPAP, mechanical ventilation or duration of hospital stay and tachypnoea. At present there is insufficient evidence to determine the efficacy and safety of salbutamol in the management of transient tachypnoea of the newborn.⁵

Systematic review⁶ found a single study that reported prophylaxis of preterm infants at risk of chronic lung disease with salbutamol led to no difference in mortality (RR 1.08, 95% CI 0.50 to...
2.31) or CLD (RR 1.03, 95% CI 0.78 to 1.37). There is no evidence for the use of salbutamol for prevention of chronic lung disease.⁶

Recommendation: There is insufficient evidence to recommend use of nebulised salbutamol in newborn infants with respiratory disease. (LOE I GOR C)

**Pharmacokinetics**

Reports describing the pharmacokinetics of intravenous salbutamol in neonates and children are limited. Kirpalani et al studied the pharmacokinetics of a single dose of intravenous salbutamol in six preterm infants (GA 24 to 28 weeks), postnatal age 54 to 105 days, with bronchopulmonary dysplasia.⁷ The elimination half-life of salbutamol was 118 minutes (range 69 to 162 minutes), volume of distribution was 1291 mL/kg (range 246 to 2997) and clearance 7.5 mL/kg/min (range 2.46 to 20.1).⁷ The authors noted that the elimination half-life in their neonates was slightly shorter than that of healthy adults.⁷

**References**


---

**Original version Date:** 18/05/2017  
**Author:** Neonatal Medicines Formulary Consensus Group  
**Current Version number:** 1.0  
**Current Version Date:** 18/05/2017  
**Risk Rating:** Medium  
**Due for Review:** 18/05/2020  
**Approval by:** JHCH CQ&PCC  
**Approval Date:** 22/08/2017